ZZ 1002
Alternative Names: ZZ-1002Latest Information Update: 11 Apr 2023
At a glance
- Originator Zhongze Therapeutics
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Schizophrenia
Most Recent Events
- 28 Mar 2023 Early research in Schizophrenia in China (unspecified route), before March 2023 (Zhongze Therapeutics pipeline, March 2023)